Clinical Trials Browser

Completed × INDUSTRY × Pathologic Complete Response × Clear all

NCT01757535 2025-07-08

QUAZAR AML-001

Phase 3 Completed

472 enrolled 24 charts 1 FDA

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT01266083 2024-11-19

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Phase 2 Completed

22 enrolled 8 charts

LymphoidOther hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02789254 2023-12-28

FLYSYN-101

Phase 1/2 Completed

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Leukemia, Myeloid, Acute

NCT00725283 2018-08-07

Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)

Phase 1 Completed

34 enrolled 10 charts

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Leukemia, Myeloid, Acute

NCT00343720 2008-03-13

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Phase 2 Completed

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis